Study of Gemcitabine and Abraxane for Pancreas Cancer

Stopped early · Phase 2

Conditions studied: Pancreatic Cancer

In brief

A Phase II trial of gemcitabine plus nab-paclitaxel in the second line setting

Key facts

Study ID

NCT02242409

Run by

Georgetown University

People needed

4

Starts

2014-09-01

Expected to finish

2016-12-01

Last updated by the study team

2017-02-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed metastatic adenocarcinoma of the pancreas
• Progression on first line non-gemcitabine based therapy for metastatic or relapsed disease
• Radiographically measurable or evaluable disease
• Age >/= 18 years
• ECOG performance status 0-2
• Adequate hepatic, bone marrow and renal function

You may not qualify if…

• Prior gemcitabine-based chemotherapy in the first line setting
• No active severe infection, or known chronic infection with HIV or hepatitis B virus
• No cardiovascular disease problems including unstable angina, therapy for life-threatening ventricular arrhythmia, or myocardial infarction, stroke, or congestive heart failure within the last 6 months
• No women who are pregnant or breastfeeding, and no women of childbearing potential without using dual forms of contraception
• Patients with known CNS metastases
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine or nab-paclitaxel
• Anticipated patient survival under 2 months

Where it is running

• Georgetown Lombardi Comprehensive Cancer Center — Washington D.C., District of Columbia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.